SPARC (SPARC)
TurnaroundFairStock Score: 36/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹197.98 |
| Market Cap | ₹6,424.88 Cr |
| P/E Ratio | 4.06 |
| ROCE | -297.83% |
| ROE | 338.67% |
| Dividend Yield | 0% |
| Profit Growth | 59.68% |
| Debt/Equity | 0.42 |
| Sales Growth | 113.93% |
| Promoter Holding | 65.67% |
| 52-Week Range | ₹108 — ₹289 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹41.26 |
Strengths
- High promoter holding of 65.67% aligns management with public shareholders and reduces corporate-governance risk.
- Reported profit growth of +14.43% suggests some improvement in the profit line, albeit from a loss-making base.
- Piotroski F-Score of 5/9 is not a zero; it shows a few signs of financial stability across the underlying metrics.
- At ₹142.88, the stock trades well below its 52-week high of ₹289, meaning much of the earlier optimism has been removed from the price.
Concerns
- Latest quarter has sales of only ₹8 crore versus a net loss of ₹81 crore; the cash burn is extreme.
- Negative book value of ₹-10.63 and N/A debt/equity point to a weak balance sheet with no positive equity cushion.
- Sales growth is -43.33%, and ROCE is -297.83%, indicating severe erosion of capital and revenue.
- With no P/E and zero dividend, there is no earnings or income support for the ₹4,124 crore market cap.
AI Analysis
Let me apply the same test I would to any business: does it earn a return on capital, does it have a durable competitive advantage, and can I estimate its future with margin of safety? SPARC fails on every count visible here. Quarterly sales are ₹8 crore, but the net loss is ₹81 crore. That is a cash furnace, not a business. Sales have fallen 43.33% from the prior period, and book value is negative at ₹-10.63. The reported ROE of 338.67% is an illusion caused by negative equity; it is not economic earning power. ROCE of -297.83% tells me the capital employed is being destroyed. The company has no earnings, so the P/E is meaningless. I cannot value a firm by hope. The market cap of ₹4,124 crore implies a great deal of future success, but the fundamentals show a deteriorating revenue base and deepening losses. The Piotroski F-Score of 5/9 is mediocre, not a strong signal. I do take some comfort from promoter holding of 65.67%, but high ownership cannot cure a bad balance sheet. There is no dividend yield, so investors must rely entirely on capital appreciation, which itself depends on a turnaround I cannot confirm. The stock is closer to its 52-week low of ₹108 than its high of ₹289, but a falling price is not an invitation when the underlying value is negative. Without profits, positive book value, or any sign of an economic moat, this is not an investment in a business; it is speculation on an uncertain outcome. In Graham's language, the margin of safety is absent. FairStock Score of 0/100 says the same. I will pass.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer